Spots Global Cancer Trial Database for Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer

Official Title: Phase II Study of Gemcitabine Plus Irinotecan in Patients With Metastatic Renal Cell Carcinoma

Study ID: NCT00401128

Conditions

Kidney Cancer

Interventions

gemcitabine hydrochloride

irinotecan hydrochloride

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving gemcitabine together with irinotecan works in treating patients with metastatic kidney cancer.

Detailed Description: OBJECTIVES: * Determine the response rate in patients with epithelial (clear or nonclear cell) renal cell carcinoma (RCC) treated with gemcitabine hydrochloride and irinotecan hydrochloride. * Compare the response in patients with clear cell RCC vs nonclear cell RCC treated with this regimen. * Determine the toxicities of this regimen. OUTLINE: This is an open-label study. Patients receive gemcitabine hydrochloride IV over 30 minutes and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Treatment repeats every 21 days for at least 6 courses in the absence of unacceptable toxicity or disease progression. After completion of study treatment, patients are followed every 3 months for 1 year. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.